Pfizer
Dina Zanetti is an accomplished professional with extensive experience in oncology and regulatory strategy management. Currently serving as the Director of Oncology Portfolio and Strategy Management at Pfizer since October 2015, Dina previously held the position of Associate Director in the same field. Prior experience includes a tenure at Bristol-Myers Squibb from September 2006 to October 2015, where responsibilities encompassed managing global regulatory strategies and preparing essential submission plans across various therapeutic areas. Earlier in career, Dina worked at Alexion Pharmaceuticals as a Manager of Supply Chain. Educational qualifications include a Master's degree in Biology from the University of Richmond and a Bachelor of Science in Biology from Adelphi University.
This person is not in any teams
This person is not in any offices
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.